FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3126678327> ?p ?o ?g. }

• W3126678327 endingPage "120350" @default.
• W3126678327 startingPage "120350" @default.
• W3126678327 abstract "Lung cancers remain the leading cause of cancer-related death in both men and women. Infiltrating immune cells in the tumor microenvironment (TME) play a critical role in the formation, progression, and the response of solid tumors to therapy, including in lung cancers. Clinical studies have established that tumor-associated macrophages (TAMs) and their phenotypical composition are critical immune infiltrates in the lung TME, with the abundance of the M2-like phenotype negatively correlating with patient survival. Colony-Stimulating Factor 1 (CSF-1) receptor (CSF-1R) is a type III protein tyrosine kinase receptor that plays an important role in the recruitment and differentiation of monocytes into tumor-promoting M2-like TAMs and their survival. In this work we evaluated the therapeutic potential of PLX 3397 (PLX), a small molecule CSF-1R inhibitor (CSF-1Ri), upon local lung administration in an immune-competent mouse model of lung cancer. The efficacy of local lung delivered PLX as single therapy was investigated first. As assessed by immunofluorescence of sections of lung tumor nodules, a statistically significant reduction in M2-like TAMs and an increase in M1-like TAMs was observed, thus leading to a shift in the (M1/M2) balance. Those changes in abundance of immune infiltrates correlated with a significant decrease in tumor burden when compared to control. When combined with systemically administered cisplatin (CIS) PLX treatment provided further benefits, leading to a significant decrease in tumor burden when compared to either PLX or CIS treatments alone, as measured by bioluminescence intensity (BLI) in vivo (thoracic area) and ex vivo (lung tissue). This combination therapy led to the most pronounced increase in M1/M2 ratio, followed by a significant decrease in M2-like TAMs with the CIS therapy. This work is clinically relevant as it demonstrates the potential of local lung administration of PLX to support standard of care chemotherapy for lung cancer management. This is important as the pulmonary route of administration is a plausible strategy for reducing the total dose of CSF-1Ris as the tissue of interest (lungs) can be locally targeted. Because the major off-target effect of CSF-1Ris is liver toxicity, reducing systemic concentration will support translation of those therapies, especially in combination with standard of care chemotherapy that has significant off-target toxicity and patient attrition itself. This work is scientifically relevant as we demonstrate for the first time that local administration of a CSF-1Ri to the lungs leads to a shift in the balance of TAMs in the TME of a model of lung tumor, adding to the sparse literature of CSF-1Ris related to lung cancers." @default.
• W3126678327 created "2021-02-15" @default.
• W3126678327 creator A5009879217 @default.
• W3126678327 creator A5011640131 @default.
• W3126678327 creator A5043465013 @default.
• W3126678327 creator A5075941140 @default.
• W3126678327 creator A5076809376 @default.
• W3126678327 date "2021-04-01" @default.
• W3126678327 modified "2023-10-17" @default.
• W3126678327 title "Pulmonary administration of a CSF-1R inhibitor alters the balance of tumor-associated macrophages and supports first-line chemotherapy in a lung cancer model" @default.
• W3126678327 cites W1546466517 @default.
• W3126678327 cites W1792045378 @default.
• W3126678327 cites W1981323713 @default.
• W3126678327 cites W1983195932 @default.
• W3126678327 cites W1997944395 @default.
• W3126678327 cites W2023164440 @default.
• W3126678327 cites W2030191482 @default.
• W3126678327 cites W2053893513 @default.
• W3126678327 cites W2054961201 @default.
• W3126678327 cites W2058648826 @default.
• W3126678327 cites W2087572503 @default.
• W3126678327 cites W2102932257 @default.
• W3126678327 cites W2127079528 @default.
• W3126678327 cites W2130253344 @default.
• W3126678327 cites W2132157071 @default.
• W3126678327 cites W2134548297 @default.
• W3126678327 cites W2141037581 @default.
• W3126678327 cites W2141390101 @default.
• W3126678327 cites W2143994426 @default.
• W3126678327 cites W2148767695 @default.
• W3126678327 cites W2161816671 @default.
• W3126678327 cites W2165831623 @default.
• W3126678327 cites W2291778524 @default.
• W3126678327 cites W2321323763 @default.
• W3126678327 cites W2338701469 @default.
• W3126678327 cites W2343682798 @default.
• W3126678327 cites W2357284749 @default.
• W3126678327 cites W2402938568 @default.
• W3126678327 cites W2415245575 @default.
• W3126678327 cites W2465595138 @default.
• W3126678327 cites W2478701956 @default.
• W3126678327 cites W2520410321 @default.
• W3126678327 cites W2582686270 @default.
• W3126678327 cites W2587532232 @default.
• W3126678327 cites W2620846290 @default.
• W3126678327 cites W2648296251 @default.
• W3126678327 cites W2728594144 @default.
• W3126678327 cites W2741206081 @default.
• W3126678327 cites W2752625590 @default.
• W3126678327 cites W2768191019 @default.
• W3126678327 cites W2777614341 @default.
• W3126678327 cites W2795292634 @default.
• W3126678327 cites W2800533919 @default.
• W3126678327 cites W2803258131 @default.
• W3126678327 cites W2889691001 @default.
• W3126678327 cites W2890107533 @default.
• W3126678327 cites W2912062069 @default.
• W3126678327 cites W2914505559 @default.
• W3126678327 cites W2919520489 @default.
• W3126678327 cites W2920580866 @default.
• W3126678327 cites W2920966707 @default.
• W3126678327 cites W2939258716 @default.
• W3126678327 cites W2947212897 @default.
• W3126678327 cites W2951394443 @default.
• W3126678327 cites W2953014078 @default.
• W3126678327 cites W2953600484 @default.
• W3126678327 cites W2967678206 @default.
• W3126678327 cites W2977642872 @default.
• W3126678327 cites W2996212786 @default.
• W3126678327 cites W2999417355 @default.
• W3126678327 cites W3022057273 @default.
• W3126678327 cites W3031508706 @default.
• W3126678327 cites W982662479 @default.
• W3126678327 doi "https://doi.org/10.1016/j.ijpharm.2021.120350" @default.
• W3126678327 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33545279" @default.
• W3126678327 hasPublicationYear "2021" @default.
• W3126678327 type Work @default.
• W3126678327 sameAs 3126678327 @default.
• W3126678327 citedByCount "6" @default.
• W3126678327 countsByYear W31266783272021 @default.
• W3126678327 countsByYear W31266783272022 @default.
• W3126678327 countsByYear W31266783272023 @default.
• W3126678327 crossrefType "journal-article" @default.
• W3126678327 hasAuthorship W3126678327A5009879217 @default.
• W3126678327 hasAuthorship W3126678327A5011640131 @default.
• W3126678327 hasAuthorship W3126678327A5043465013 @default.
• W3126678327 hasAuthorship W3126678327A5075941140 @default.
• W3126678327 hasAuthorship W3126678327A5076809376 @default.
• W3126678327 hasConcept C121608353 @default.
• W3126678327 hasConcept C126322002 @default.
• W3126678327 hasConcept C142724271 @default.
• W3126678327 hasConcept C203014093 @default.
• W3126678327 hasConcept C2776107976 @default.
• W3126678327 hasConcept C2776256026 @default.
• W3126678327 hasConcept C2776694085 @default.
• W3126678327 hasConcept C2777701055 @default.
• W3126678327 hasConcept C2777714996 @default.
• W3126678327 hasConcept C2778239845 @default.

• next